img

Global Blood Tumor Treatment Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034


Published on: 2024-01-04 | No of Pages : 411 | Industry : Pharma & Healthcare

Publisher : GRD Survey | Format : PDF

Global Blood Tumor Treatment Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034

Executive Summary

According to GRD Survey data, the global Blood Tumor Treatment market is estimated at million US$ in 2021 and is expected to reach million US$ by the end of 2028, growing at a CAGR of % in the forecast period between 2022 and 2028.

This report studies the Blood Tumor Treatment market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Blood Tumor Treatment in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
Chemotherapy
Targeted Therapy
Immunotherapy
Other

Market Snapshot, By Application
Leukemia
Lymphoma
Multiple Myeloma
Others

Main Market Players Analyzed in this report, including
Takeda
Roche
Pfizer
Novartis
Johnson & Johnson
Gilead Sciences
Bristol-Myers Squibb
AstraZeneca
Amgen
AbbVie

The study objectives of this report are
To study and analyze the global Blood Tumor Treatment market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Blood Tumor Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Blood Tumor Treatment manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Blood Tumor Treatment market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Blood Tumor Treatment submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Blood Tumor Treatment are as follows
History Year2016-2020
Base Year2020
Estimated Year2021
Forecast Year 2021 to 2027

This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Content

Global Blood Tumor Treatment Industry Outlook 2022: Overview, Opportunities, Key Companies and Forecast to 2028.pdf

List of Figure

Table of Contents

1 Market Definition & Scope
1.1 Definition & Scope
1.2 Blood Tumor Treatment Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Blood Tumor Treatment Market Performance and Outlook

2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Blood Tumor Treatment

3 Supply Chain and Manufacturing Cost Analysis
3.1 Supply Chain Analysis
3.2 Raw Materials and Key Suppliers Analysis
3.2.1 Raw Materials Introduction
3.2.1 Raw Materials Key Suppliers List
3.3 Blood Tumor Treatment Sales Channel and Distributors Analysis
3.3.1 Blood Tumor Treatment Sales Channel
3.3.2 Blood Tumor Treatment Distributors
3.4 Key Buying Industries/Consumers
3.4.1 Major Buyers in Leukemia
3.4.2 Major Buyers in Lymphoma
3.5 Blood Tumor Treatment Manufacturing Cost Structure Analysis

4 Market Segment: by Type
4.1 Blood Tumor Treatment Type Introduction
4.1.1 Chemotherapy
4.1.2 Targeted Therapy
4.1.3 Immunotherapy
4.1.4 Other
4.2 Global Blood Tumor Treatment Sales by Type 2016-2021
4.3 Global Blood Tumor Treatment Revenue by Type 2016-2021
4.4 Global Blood Tumor Treatment Price by Type 2016-2021

5 Market Segment: by Application
5.1 Blood Tumor Treatment Type Introduction
5.1.1 Leukemia
5.1.2 Lymphoma
5.1.3 Multiple Myeloma
5.1.3 Others
5.2 Global Blood Tumor Treatment Sales by Application 2016-2021
5.3 Global Blood Tumor Treatment Revenue by Application 2016-2021
5.4 Global Blood Tumor Treatment Price by Application 2016-2021

6 Marke Segment: by Region
6.1 Global Blood Tumor Treatment Market by Region
6.1.1 Global Blood Tumor Treatment Sales by Regions
6.1.2 Global Blood Tumor Treatment Revenue by Regions
6.2 North America Blood Tumor Treatment Market 2016-2021
6.3 Europe Blood Tumor Treatment Market 2016-2021
6.4 Asia Pacific Blood Tumor Treatment Market 2016-2021
6.5 South America Blood Tumor Treatment Market 2016-2021
6.6 Middle East and Africa Blood Tumor Treatment Market 2016-2021

7 North America
7.1 North America Blood Tumor Treatment Market by Country 2016-2021
7.1.1 North America Blood Tumor Treatment Sales by Country
7.1.2 North America Blood Tumor Treatment Revenue by Country
7.2 United States
7.3 Canada
7.4 Mexico

8 Europe
8.1 Europe Blood Tumor Treatment Market by Country 2016-2021
8.1.1 Europe Blood Tumor Treatment Sales by Country
8.1.2 Europe Blood Tumor Treatment Revenue by Country
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain

9 Asia Pacific
9.1 Asia Pacific Blood Tumor Treatment Market by Country 2016-2021
9.1.1 Asia Pacific Blood Tumor Treatment Sales by Country
9.1.2 Asia Pacific Blood Tumor Treatment Revenue by Country
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia

10 South America
10.1 South America Blood Tumor Treatment Market by Country 2016-2021
10.1.1 South America Blood Tumor Treatment Sales by Country
10.1.2 South America Blood Tumor Treatment Revenue by Country
10.2 Brazil
10.3 Argentina
10.4 Colombia

11 Middle East and Africa
11.1 Middle East and Africa Blood Tumor Treatment Market by Country 2016-2021
11.1.1 Middle East and Africa Blood Tumor Treatment Sales by Country
11.1.2 Middle East and Africa Blood Tumor Treatment Revenue by Country
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa

12 Key Participants Company Information
12.1 Takeda
12.1.1 Takeda Company Information
12.1.2 Takeda Blood Tumor Treatment Product Portfolio, Specification and Application
12.1.3 Takeda Blood Tumor Treatment Sales, Price, Revenue and Gross Margin (2019-2021)
12.1.4 Takeda Key Development
12.2 Roche
12.2.1 Roche Company Information
12.2.2 Roche Blood Tumor Treatment Product Portfolio, Specification and Application
12.2.3 Roche Blood Tumor Treatment Sales, Price, Revenue and Gross Margin (2019-2021)
12.2.4 Roche Key Development
12.3 Pfizer
12.3.1 Pfizer Company Information
12.3.2 Pfizer Blood Tumor Treatment Product Portfolio, Specification and Application
12.3.3 Pfizer Blood Tumor Treatment Sales, Price, Revenue and Gross Margin (2019-2021)
12.3.4 Pfizer Key Development
12.4 Novartis
12.4.1 Novartis Company Information
12.4.2 Novartis Blood Tumor Treatment Product Portfolio, Specification and Application
12.4.3 Novartis Blood Tumor Treatment Sales, Price, Revenue and Gross Margin (2019-2021)
12.4.4 Novartis Key Development
12.5 Johnson & Johnson
12.5.1 Johnson & Johnson Company Information
12.5.2 Johnson & Johnson Blood Tumor Treatment Product Portfolio, Specification and Application
12.5.3 Johnson & Johnson Blood Tumor Treatment Sales, Price, Revenue and Gross Margin (2019-2021)
12.5.4 Johnson & Johnson Key Development
12.6 Gilead Sciences
12.6.1 Gilead Sciences Company Information
12.6.2 Gilead Sciences Blood Tumor Treatment Product Portfolio, Specification and Application
12.6.3 Gilead Sciences Blood Tumor Treatment Sales, Price, Revenue and Gross Margin (2019-2021)
12.6.4 Gilead Sciences Key Development
12.7 Bristol-Myers Squibb
12.7.1 Bristol-Myers Squibb Company Information
12.7.2 Bristol-Myers Squibb Blood Tumor Treatment Product Portfolio, Specification and Application
12.7.3 Bristol-Myers Squibb Blood Tumor Treatment Sales, Price, Revenue and Gross Margin (2019-2021)
12.7.4 Gilead Sciences Key Development
12.9 Amgen
12.9.1 Amgen Company Information
12.9.2 Amgen Blood Tumor Treatment Product Portfolio, Specification and Application
12.9.3 Amgen Blood Tumor Treatment Sales, Price, Revenue and Gross Margin (2019-2021)
12.9.4 Amgen Key Development
12.8 AstraZeneca
12.8.1 AstraZeneca Company Information
12.8.2 AstraZeneca Blood Tumor Treatment Product Portfolio, Specification and Application
12.8.3 AstraZeneca Blood Tumor Treatment Sales, Price, Revenue and Gross Margin (2019-2021)
12.8.4 AstraZeneca Key Development

13 Global Blood Tumor Treatment Market Forecast by Region by Type and by Application
13.1 Global Blood Tumor Treatment Sales, Revenue Forecast 2022-2027
13.2 Global Blood Tumor Treatment Forecast by Regions
13.2.1 Global Blood Tumor Treatment Sales Forecast by Region 2022-2027
13.2.2 Global Blood Tumor Treatment Revenue Forecast by Region 2022-2027
13.3 Global Blood Tumor Treatment Forecast by Type
13.3.1 Global Blood Tumor Treatment Sales Forecast by Type 2022-2027
13.3.2 Global Blood Tumor Treatment Revenue Forecast by Type 2022-2027
13.3.3 Global Blood Tumor Treatment Price Forecast by Type 2022-2027
13.4 Global Blood Tumor Treatment Forecast by Application
13.4.1 Global Blood Tumor Treatment Sales Forecast by Application 2022-2027
13.4.2 Global Blood Tumor Treatment Revenue Forecast by Application 2022-2027
13.4.3 Global Blood Tumor Treatment Price Forecast by Application 2022-2027

14 Analyst Views and Conclusions

15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer